Menu
← Oncology Approval Tracker
FDA DECISION ·
Nypozi
filgrastim-txid · Tanvex BioPharma USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Filgrastim biosimilar for labeled uses including reducing infection associated with chemotherapy-related febrile neutropenia, shortening neutrophil recovery after AML chemotherapy or marrow transplant, and mobilizing autologous peripheral blood progenitor cells.
LAMPGEN ANALYSIS
Why it matters
A Neupogen biosimilar adds another G-CSF product for supportive care and transplant workflows.
What research teams should watch
Standardize biosimilar naming and lot capture and check that each ordered syringe and route matches the indication.
PRIMARY RECORDS